Effective management of HR-positive, HER2-negative Breast Cancer in younger women requires special consideration to help improve outcomes, as this group is more likely to experience late recurrence. What factors lead to delayed detection in younger women at risk?

Reflecting on an incredible #ASH25 in Orlando! The Lilly team described in one word what being part of this global #Hematology congress meant to them. Proud to stand united in advancing science and shaping the future of patient care.

Thank you to the #Hematology community for an inspiring week at #ASH25. We’re grateful for the meaningful conversations and shared dedication to advancing hematology care. We look forward to continuing the conversation

Which ASH 2025 finding was most practice-changing for you? Share your reasoning in the comments below.

Behind every #CLL diagnosis is a personal journey. Join us at #ASH25 to explore how science and compassion intersect in delivering full-spectrum care.

Lilly is live at #ASH25, where every conversation helps bring us closer to better care. Explore how we're leading change in #CLL care and join our booth for expert discussions and new perspectives in #Hematology.

Behind every breakthrough at #ASH25 is a patient, a story, and a purpose. We’re honored to join a global community committed to advancing #Hematology through science and innovation. Follow us for updates that matter.

Interested in education before #ASH25 begins? 🗓️ Lilly is proud to support an independent symposium where #Hematology experts share the latest on #CLL and SLL: unmet needs, emerging approaches, managing adverse events, and key takeaways for advancing care. 👉Register now!

Watch as Dr. Marcelo Pitombeira de Lacerda explores how genetic risk, management history, and patient preferences guide sequencing strategies. With few direct comparisons, clinical judgment remains critical in #CLL care.

#ASH25 unites the brightest experts in #Hematology—and Lilly is proud to be part of it. From emerging data to evolving care strategies, we’re here to share and learn alongside the community. Follow us as we help shape what’s next.

Multidisciplinary teams—including clinicians, nurses, pharmacists, and supportive care specialists—play a vital role in patient safety in metastatic #BreastCancer by identifying, managing, and mitigating adverse events, ensuring treatment continuity and better outcomes.

Which approach to patient support has most positively impacted adherence and outcomes in your CLL practice?

Many #EarlyBreastCancer survivors live with persistent fear of recurrence, affecting their mental health and decisions. This underscores the need for strong risk communication and ongoing psychosocial support.

Adherence to therapy is essential for effective #BreastCancer care, yet many patients struggle to follow their regimen, facing up to twice the risk of relapse or mortality. What strategies do you use to improve treatment adherence for your patients?

Discover why the timing of treatment in #CLL matters just as much as the approach. Dr. @MosqueraOrgeira explores how disease activity, biomarkers, and patient context guide smarter, more personalized decisions.

Confidence in spotting subtle changes in your #CLL patients can make all the difference. How do you stay vigilant for early progression and decide when to adjust therapy?

As #BreastCancerAwarenessMonth comes to a close, the conversation doesn’t stop. It’s crucial to continue raising awareness about early detection, risk factors, and the broader impact of breast cancer. Let’s keep talking—today and every day ahead!

Discover why Overall Survival (OS) remains the gold standard for assessing treatment benefits in cancer care. Hear from Professor Marc Thill as he explains the importance of OS in #EarlyBreastCancer trials and its role in guiding therapeutic goals.

From the first touch of self-exam, to the hands of care, the supportive grip from loved ones, and the hands advancing research –#BreastCancer survivorship is a collective effort. #BreastCancerAwarenessMonth

Treatment changes in #CLL aren’t just physical—they’re emotional too. What’s your approach to empowering patients through these shifts?